The gold complex auranofin sensitizes platinum resistant epithelial ovarian cancer cells to cisplatin

IF 2.3 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry and Biophysics Reports Pub Date : 2025-03-29 DOI:10.1016/j.bbrep.2025.101996

Farah H. Abdalbari , Benjamin N. Forgie , Edith Zorychta , Alicia A. Goyeneche , Abu Shadat M. Noman , Carlos M. Telleria

引用次数: 0

Abstract

Although numerous drugs have been tested to treat ovarian cancer (OC), survival rates remain low as there has been no major improvement from platinum (Pt)–based therapy and there is a high rate of Pt resistance in these tumors. Following several rounds of chemotherapy, OC cells develop Pt-resistance by increasing DNA repair and antioxidant defense mechanisms. This study aimed to design a treatment to combat recurrent stages of OC by repurposing the anti-rheumatic gold complex auranofin (AF). We demonstrate that AF enhances the efficacy of cisplatin (CDDP) in Pt-resistant epithelial OC (EOC) cells. The drug combination enhanced mitochondrial-dependent apoptosis, PARP cleavage, DNA damage, and ROS overproduction. These results suggest the potential to combine AF with CDDP as a strategy to improve CDDP sensitivity in recurrent EOCs.

查看原文本刊更多论文

尽管已经测试了多种治疗卵巢癌（OC）的药物，但由于铂（Pt）疗法没有明显改善，而且这些肿瘤对铂的耐药率很高，因此存活率仍然很低。经过几轮化疗后，OC细胞会通过增加DNA修复和抗氧化防御机制来产生铂抗性。本研究旨在通过重新利用抗风湿金复合物auranofin（AF）来设计一种治疗方法，以对抗OC的复发阶段。我们证明，AF能增强顺铂（CDDP）对铂耐药上皮性OC（EOC）细胞的疗效。联合用药增强了线粒体依赖性凋亡、PARP裂解、DNA损伤和ROS过量产生。这些结果表明，AF与CDDP联合用药有可能提高复发性EOC对CDDP的敏感性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemistry and Biophysics Reports Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

4.60

自引率

0.00%

发文量

191

审稿时长

59 days

期刊介绍： Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.